At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 48 enrolled
Drug / intervention
afliberceptdrug
Likely dose
aflibercept 30Gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
In Brief
A Phase 4 clinical trial evaluating aflibercept for Exudative Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Completed, enrolled 48 participants across 8 sites.
Detailed Summary
Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
CollaboratorsBayer
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedSep 2013
Primary CompletionMay 2015
Study CompletionAug 2015
TodayJul 2026
First PostedSep 25, 2013
Enrollment StartSep 1, 2013
Primary CompletionMay 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 12.8 years ago
Interventions
afliberceptdrug
Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.